-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-522074-37-00
4
2026-02-19
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension Associat
-
2024-519844-34-03
4
2026-01-19
Treatment Resistant Depression (TRD)
-
2024-517980-22-00
4
2025-12-10
Multiple Sclerosis (MS)
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2025-520747-32-00
5
2025-10-29
Mild to moderate Alzheimer’s Disease
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2023-509275-17-00
5
2025-10-06
Relapsing multiple sclerosis
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-518563-35-00
4
2025-08-25
Alzheimer's Disease
-
2023-503634-50-01
5
2025-07-22
Anemia in patients with chronic kidney disease on dialysis
-
2024-519282-22-00
5
2025-07-09
Chronic Hepatitis D Virus (HDV) Infection
-
2024-517423-40-00
5
2025-06-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-517545-13-00
11
2025-06-04
Neovascular Age-Related Macular Degeneration
-
2024-519116-14-00
4
2025-05-27
Asthma
-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-515934-34-00
6
2025-01-28
Low-cardiac output syndrome (LCOS)
-
2023-506675-96-00
5
2025-01-23
Heart Failure
-
2024-517863-22-00
5
2024-12-01
Study population consists in patients with a diagnosis of mCRC who hav
-
2024-512895-36-00
5
2024-11-25
Metabolic Dysfunction-Associated Steatohepatitis (MASH)